Osteoclast Impairment in Chronic Periodontitis by Regenerative Materials.

July 24, 2017 updated by: Dr.Jaideep Mahendra, Meenakshi Ammal Dental College and Hospital

Platelet Rich Fibrin/Biphasic Calcium Phosphate Impairs Osteoclasts Differentiation and Promotes Apoptosis by the Intrinsic Mitochondrial Pathway in Chronic Periodontitis

The present study is an effort to investigate the hypothesis that Platelet Rich Fibrin/Biphasic Calcium Phosphate may play a role in inhibiting osteoclasts differentiation and in bone loss.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Study design

Fifty-five individuals from a suburban population were recruited. Out of them, 5 individuals refused to participate in the study. Finally, 50 participants were selected and divided into two groups, control group [Healthy individuals]: 25 Males/Females, aged 25 to 35 years and test group [Chronic periodontitis patients]: 25 Males/Females aged 30 to 45 years.

Demographic variables and periodontal parameters were measured in both the groups.The investigators explored the effect of Platelet rich fibrin (PRF)/Biphasic calcium phosphate (BCP) on differentiation and survival of osteoclasts obtained from peripheral blood of Chronic Periodontitis patients.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 35 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria: (Control group)

  • Subjects with age group between 30 to 45 years.
  • Non-smokers.
  • No previous history of periodontal treatment.

Inclusion Criteria: (Test group)

  • Subjects with age group between 30 to 45 years.
  • Presence of atleast 20 teeth
  • More than 30% of the sites with clinical attachment loss.
  • Non-smokers.
  • No previous history of periodontal treatment.

Exclusion Criteria: ( both the groups)

  • Individuals with systemic disease
  • Subjects under antibiotics or anti-inflammatory drugs within the previous 3 months.
  • Pregnant and lactating women.
  • Allergic to antibiotics.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Test group
Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
Other Names:
  • others : BCP
  • others : PRF/BCP combination
OTHER: control group
Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
Other Names:
  • others : BCP
  • others : PRF/BCP combination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
probing pocket depth
Time Frame: base line
probing pocket dept was measured using Williams periodontal probe at base line
base line

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Protein expression on osteoclast cells was estimated with BCP, PRF alone and BCP/PRF combination.
Time Frame: 24 hours from baseline
Protein expression on cells was analyzed using Western blot in all the groups
24 hours from baseline
The activity of caspase-3 in OCs.
Time Frame: 24 hours from base line
The activity of caspase-3 was seen in OCs in all the groups
24 hours from base line

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: shila samuel, MS, PhD, VRR diagnostic institute chennai
  • Principal Investigator: jaideep mahendra, MDS,PhD, meenakshi ammal dental college chennai

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 17, 2014

Primary Completion (ACTUAL)

April 13, 2016

Study Completion (ACTUAL)

March 18, 2017

Study Registration Dates

First Submitted

June 25, 2017

First Submitted That Met QC Criteria

July 21, 2017

First Posted (ACTUAL)

July 24, 2017

Study Record Updates

Last Update Posted (ACTUAL)

July 26, 2017

Last Update Submitted That Met QC Criteria

July 24, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontal Bone Loss

Clinical Trials on other : PRF

Subscribe